Lipocine Inc. (LPCN)
LPCN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/0001493152-26-009411-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LPCN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001535955 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.0M |
| Net income | -$9.6M |
| Operating income | -$10.4M |
| Net margin | -487.1% |
| Operating margin | -524.7% |
| Revenue growth | -82.3% |
| Cash | $5.2M |
| Total assets | $17.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $2.6M cash; operating cash flow -$2.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 11,073,439 (2026-11-04); 5,551,931 a year earlier; 5,315,830 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | 1; latest on 2024-10-23 | Source 2024-10-23 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-02-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Tanner LLP, Salt Lake City, Utah, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $462K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $2.3M | -$666K | -$1.8M | $2.6M | No debt tags | $3.7M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $190K | -$2.6M | -$3.0M | $5.0M | No debt tags | $1.6M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $119K | -$3.7M | -$2.3M | $5.0M | No debt tags | $2.0M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $1.1M | -$2.4M | -$2.9M | $5.2M | No debt tags | $2.0M | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | $115K | -$3.2M | -$3.0M | $3.9M | No debt tags | $4.3M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $623K | -$2.2M | -$1.9M | $6.0M | No debt tags | $4.2M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $94K | -$1.9M | -$2.0M | $3.4M | No debt tags | $3.7M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $3.5M | $1.8M | $1.7M | $6.2M | No debt tags | $11.2M | 10-K 2026-03-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-26 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 825 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +8.9% |
| 1 month | +5.6% |
| 3 months | -17.0% |
| Year to date | -78.7% |
| 1 year | -39.4% |
| From 52-week high | -84.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| COCP | Cocrystal Pharma Inc. | $0.9777 | -0.24% | $18.8M |
| ATOS | Atossa Therapeutics Inc. | $1.93 | -1.53% | $19.3M |
| QNRX | Quoin Pharmaceuticals Ltd. | $3.56 | -3.78% | $17.1M |
| AYTU | Aytu BioPharma Inc. | $1.82 | +1.68% | $19.8M |
| CELU | Celularity Inc. | $0.6191 | -1.75% | $20.1M |
| SHPH | Shuttle Pharmaceuticals Holdings Inc. | $4.24 | -6.40% | $20.2M |
| KTTA | Pasithea Therapeutics Corp. | $0.5000 | -4.21% | $16.7M |
| IGC | IGC Pharma Inc. | $0.1750 | -0.57% | $20.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier